Xponance Inc. Acquires 3,551 Shares of Humana Inc. (NYSE:HUM)

Xponance Inc. lifted its stake in Humana Inc. (NYSE:HUM - Free Report) by 20.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,200 shares of the insurance provider's stock after purchasing an additional 3,551 shares during the period. Xponance Inc.'s holdings in Humana were worth $5,610,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares in the last quarter. Dodge & Cox grew its holdings in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Geode Capital Management LLC grew its holdings in Humana by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after acquiring an additional 63,562 shares during the period. Invesco Ltd. grew its holdings in Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after acquiring an additional 550,692 shares during the period. Finally, Norges Bank acquired a new stake in Humana during the 4th quarter worth $416,202,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Down 0.8%

HUM traded down $1.80 during trading on Friday, hitting $230.38. The company had a trading volume of 1,077,538 shares, compared to its average volume of 1,817,839. The company has a market capitalization of $27.81 billion, a PE ratio of 16.29, a PEG ratio of 1.74 and a beta of 0.44. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The firm's 50-day moving average price is $237.78 and its 200 day moving average price is $258.33. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm's revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.23 EPS. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.54%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on HUM shares. Oppenheimer lifted their target price on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, May 1st. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. Finally, Truist Financial set a $280.00 target price on shares of Humana and gave the stock a "hold" rating in a report on Tuesday, June 17th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Humana has an average rating of "Hold" and a consensus target price of $280.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.